Pharmacists in Harlingen, Texas


91 Pharmacists found in Harlingen
female pharmacist

Shannon Garza, PHARM.D.


Pharmacist - Clinician (PhC)/ Clinical Pharmacy Specialist
801 N Ed Carey Dr, Harlingen, TX 78550
956-254-6562    

male pharmacist

Dr. Shawn Jeffery Prieskorn, PHARMD


Pharmacist
2106 Treasure Hills Blvd, Harlingen, TX 78550
956-366-4557    

male pharmacist

Dr. Stephen Eric Grayson, PHARM.D.


Pharmacist
305 E Jackson St, Suite 112, Harlingen, TX 78550
956-425-1799     888-748-3291



male pharmacist

Stephen A Stout


Pharmacist
101 S Stuart Place Rd Ste F, Harlingen, TX 78552
956-368-5060     956-368-5061

male pharmacist

Terrence William Kennedy, PHARMACIST


Pharmacist
1406 E Harrison Ave, Harlingen, TX 78550
956-412-8362     956-412-8451

male pharmacist

Timothy Carl Ritter, M.S., R.PH.


Pharmacist
2601 Veterans Dr, Harlingen, TX 78550
618-697-0320    

male pharmacist

Dr. Tuan Anh Mai, PHARMD


Pharmacist
1921 S 77 Sunshinestrip, Harlingen, TX 78550
956-365-3035     956-365-3029

female pharmacist

Dr. Veronica Sueli Tovar, PHARMD


Pharmacist - Clinician (PhC)/ Clinical Pharmacy Specialist
2106 Treasure Hills Blvd, Harlingen, TX 78550
956-752-0749    

female pharmacist

Veronica Schubert, PHARMD


Pharmacist
1719 Treasure Hills Blvd, Harlingen, TX 78550
956-364-2131     956-364-2141

male pharmacist

Dr. Vicente Antonio Flores, PHARM D


Pharmacist
2015 S 77 Sunshinestrip, Harlingen, TX 78550
956-423-2986    

female pharmacist

Dr. Yetunde Omotola Faleye, PHARMD


Pharmacist - Pharmacotherapy
2101 Pease St, Harlingen, TX 78550
956-389-1975    


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.